shutterstock_1816265087_michael_vi

Michael Vi / Shutterstock.com

29 September 2020AmericasMuireann Bolger

Janssen sues Mylan to block generic of schizophrenia drug

A Johnson & Johnson (J&J) company, Janssen Pharmaceuticals, is seeking a court order blocking Mylan from making copies of its schizophrenia treatment, Invega Trinza, until its patent expires in 2036.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Janssen acquires anti-depressant drug in $25m deal

17 August 2017 Janssen, a subsidiary of Johnson & Johnson, has acquired an anti-depressant drug candidate in a $25 million deal with Cerecor.

Janssen sells five drugs for $155m

12 October 2016 India-based Piramal Enterprises has signed an agreement with Belgian pharmaceutical company Janssen under which Piramal will acquire five anaesthesia and pain management products for $155 million in cash.

Mylan asks SCOTUS to end NHK-Fintiv rule

16 August 2021 Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.

More on this story

Janssen acquires anti-depressant drug in $25m deal

17 August 2017 Janssen, a subsidiary of Johnson & Johnson, has acquired an anti-depressant drug candidate in a $25 million deal with Cerecor.

Janssen sells five drugs for $155m

12 October 2016 India-based Piramal Enterprises has signed an agreement with Belgian pharmaceutical company Janssen under which Piramal will acquire five anaesthesia and pain management products for $155 million in cash.

Mylan asks SCOTUS to end NHK-Fintiv rule

16 August 2021 Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.

More on this story

Janssen acquires anti-depressant drug in $25m deal

17 August 2017 Janssen, a subsidiary of Johnson & Johnson, has acquired an anti-depressant drug candidate in a $25 million deal with Cerecor.

Janssen sells five drugs for $155m

12 October 2016 India-based Piramal Enterprises has signed an agreement with Belgian pharmaceutical company Janssen under which Piramal will acquire five anaesthesia and pain management products for $155 million in cash.

Mylan asks SCOTUS to end NHK-Fintiv rule

16 August 2021 Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.

More features

Amgen faces pushback over bid to narrow patent scope

LSPN Europe: Navigating the EPO and lessons from the UPC frontline

Paul Hastings reinforces London office with high-tech patent litigator

Gene tech firm fends off injunction in test kit dispute

Comparing life sciences IP in Brazil and the US

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan